East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bromfenac Ophthalmic Solution 0.09%. Aurobindo Pharma’s Bromfenac Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), Bromday™ Ophthalmic Solution, of Bausch & Lomb.

Bromfenac Ophthalmic Solution are indicated for:

• Postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery